1489 studies found for:    "Melanoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Melanoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental;   Experimental Melanomas
Interventions: Biological: aldesleukin;   Biological: therapeutic autologous lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine phosphate;   Radiation: Total body irradiation
2 Terminated
Has Results
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
3 Completed Phase II Trial of Allovectin-7® for Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Malignant Melanoma;   Skin Cancer
Intervention: Genetic: Allovectin-7®
4 Recruiting FDG-PET in Advanced Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Radiation: [18F]fluorodeoxyglucose;   Other: Molecular assays on biopsied tissue;   Device: positron emission tomography;   Device: computed tomography
5 Not yet recruiting Combi-Neo Study for Stage IV Melanoma
Conditions: Melanoma;   Malignant Melanoma Stage IV;   Metastatic Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Procedure: Surgery
6 Terminated A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Metastatic Melanoma
Intervention: Drug: 131I-TM601
7 Withdrawn Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Conditions: Melanoma;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus
8 Recruiting Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
9 Completed Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Intervention: Drug: allovectin-7
10 Completed Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: allovectin-7;   Drug: allovectin-7/dacarbazine;   Drug: dacarbazine
11 Completed Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: dendritic cell-gp100-MART-1 antigen vaccine;   Drug: sargramostim
12 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
13 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
14 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
15 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
16 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
17 Recruiting Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention: Drug: Pazopanib and Paclitaxel
18 Completed Vaccine Therapy in Treating Patients With Advanced Melanoma
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Procedure: biopsy
19 Completed Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: ipilimumab
20 Unknown  FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Intervention: Drug: romidepsin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years